RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $280
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $345 to $280.
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $345 to $280.